Studies have shown that active fund managers routinely underperform the S&P500 index*​

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

SRPT Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-15.50%
Analyst Rating:
HOLD
Analyst Forecast (1yr):
35%

SRPT Stock Analysis

SRPT PE Ratio: 77.3

SRPT PEG Ratio: Not Available

SRPT Forward EPS Growth (12 month): 0.00%

SRPT PS Ratio: 0.8

SRPT PSG Ratio: Not Available

SRPT Forward Revenue Growth (12 month): 0.00%

SRPT Articles

No data was found